“The 9th National Conference of the CNSLD” was held in the Beijing International Convention Center (BICC), hosted by Wu Jieping Medical Foundation, CNSLD, BMA, and THI at CMU, supported by EASL, CSH and other organizations from June 2 to June 4.
Beijing International Convention Center
The 9th National Conference of the CNSLD
Hepatitis B tops among the four infectious diseases under major prevention and control in China, great national attention is paid to treatment of Hepatitis B. The listing conference of Cosunter‘s FGD for CHB indications - Fuganding® TDF was held on June 4.
Listing Conference of Fuganding
At the beginning of the conference, Professor Duan Zhongping, the Chairman of Chinese Society of Hepatology, CMA, spoke highly of Cosunter’s contribution to liver diseases treatment in China. It is said that Cosunter has not only provide quality anti-virus drugs for patients with liver cancer, but also participated in 7 major special programs during the “National 11th Five-Year Plan Period” and “National 12th Five-Year Plan Period”, making its unremitting efforts to improve chronic hepatitis B (CHB) treatment.
Professor Duan Zhongping, the Chairman of Chinese Society of Hepatology,CMA
Professor Ren Hong from the Second Affiliated Hospital of Chongqing Medical University, as the lead researcher of Fuganding Phase III clinical research, released the result of the three-year clinic study for TDF-ETV non-inferiority control trial.
Professor Ren Hong from the Second Affiliated Hospital of Chongqing Medical University
Research shows that: If patients are treated with TDF for 12 weeks, HBV DNA of 97.2% patients declines by 2 logIU/ml; for 144 weeks, median HBV DNA declines by 6.7 log10 IU/ml and 94.5% patients experience HBV DNA negative conversion, 31% patients experience HBeAg negative conversion, 90.8% recover normal liver functions, with drug tolerance rate being 0. TDF is recommended to be the priority treatment drugs for untreated patients in guides of various countries.
Professor Xie Qing from Ruijin Hospital Shanghai Jiaotong Uninersity School of Medicine mainly introduced the effectiveness of Fuganding. TDF or combination with TDF is recommended to the patients who take “lamivudine”, “telbivudine”, “adefovir”, “entecavir” and those with multiple drug tolerance among the guides of recommended drugs to treat CHB patients in various countries.
Professor Xie Qing from Ruijin Hospital Shanghai Jiaotong Uninersity School of Medicine
Professor Gao Zhiliang from the Third Affiliated Hospital of Zhongshan University focused on the safety of TDF. TDF has a low rate in adverse events occuring to kidney and bones, which may be avoided through monitoring and adjustment of dosage. TDF is rated as B-type drug for pregnant women by the Food and Drug Administration (FDA) of America, with a greater safety for pregnant patients than other medcines. It is also the only nucleotide analog recommended to be suitable for pregnant patients in the new EASL.
Professor Gao Zhiliang from the Third Affiliated Hospital of Zhongshan University
In the end of the academic report session, Professor Jia Jidong from Beijing Friendship Hospital, Capital Medical University, gave an impressive conclusion of what the above three experts have introduced:
1. TDF reduces poor response to CHB antiviral therapy due to its greater antiviral effectiveness;
2. TDF has been put into use for over eight years, and no drug tolerance is found for both untreated and treated patients, so it is a good option to keep away from drug tolerance over long-term treatment;
3. TDF is a B-type drug for pregnant women. It’s the only recommendation for pregnant patients in the new EASL. It reduces impact to patients during pregancy.
Professor Jia Jidong from Beijing Friendship Hospital, Capital Medical University
At the same time, Professor Chen Chengwei, the chief editor of the magazine Chinese Hepatology, focused on matters regarding the “setup of Outstanding Contribution to China’s Hepatopathy”, and expressed thanks to Cosunter’s outstanding contribution to treatment of liver diseases, on behalf of the Association of Chinese Journal of Liver Diseases.
Chen Chengwei, the Chief Editor of the magazine Chinese Hepatology
The listing ceremony for Fuganding was presided by Zhuang Hui, an academician of Chinese Academy of Engineering. Over ten Chinese well-renowned experts jointly lit up the colored lanterns for “Fuganding-Tenofovir Dipyride Fumarate Capsules”, which has a far-reaching significance. The “Fuganding” carrier has begun its journey into the vast ocean of severe liver diseases treatment since then.
Colored lanterns ceremony for “Fuganding-Tenofovir Dipyride Fumarate Capsules”
As a new generation of anti-HBV medicine, TDF is recommended as the best choice for chronic hepatitis B (CHB) treatment in the CHB prevention guides of all countries, due to its powerful effect, relative safety and no drug tolerance in eight consecutive years.
In 2007, Consunter took the lead in China to begin the research of TDF and won extensive support from the major special scientific projects for the “11th Five-Year Plan” and “12th Five-Year Plan” of Fujian Province. Thanks to ten years of efforts and a cost of about RMB 50 million, it managed to complete the first multi-centered clinical and experimental study to non-inferiority of two priority medicines TDF-ETV across the globe. Given the achievement, it won the first approval for production of TDF for HBV indications in China, thus posing a challenge to patents of foreign enterprises, breaking the high-priced monopoly of imported medicines. All these promote vast production of anti-HBV medicines of a new generation in China for the great benefit of Chinese hepatitis-B patients.
TDF has been listed into the National Reimbursement Drug List (NRDL) in 2017. Approval of TDF bulk drug and capsules in May, 2017 helps Cosunter become the only enterprise to have the two priority anti-HBV medicines of TDF and ETV, with the most complete production line in the anti-HBV field in China, so that it leads in the China’s market for anti-HBV medicines.